On September 3, 2026, Senti Biosciences Holdings completed the issuance of $2.0 million in Senior Secured Convertible Notes to NSG BioInnovation Fund under a Securities Purchase Agreement dated April 27, 2026. The company also entered into an equity commitment letter with an affiliate of Celadon Partners, LLC, agreeing to sell $2.5 million of common stock at the Nasdaq Minimum Price around the time of a merger closing. These transactions are part of broader Subject Transactions involving a potential merger and contingent value rights that may pay up to $60.0 million based on regulatory and sales milestones for product candidate SENTI-202. A preliminary proxy statement was filed on July 21, 2026, with definitive materials expected soon. Senti Biosciences Holdings operates in the biotechnology industry, developing immunotherapies.

Senti Biosciences Holdings, Inc. amended its Securities Purchase Agreement to authorize the issuance of a third tranche of Senior Secured Convertible Notes valued at $2.0 million to NSG BioInnovation Fund, L.P., satisfying Celadon Partners SPV 35 Limited’s remaining purchase obligation under a July 14, 2026 merger agreement. Simultaneously, the Company received Nasdaq notices for non-compliance with minimum bid price and stockholders’ equity requirements due to a closing bid price below $1.00 and a deficit of $3,401,000 as of June 30, 2026. The Company has until February 23, 2027, to regain bid price compliance and October 11, 2026, to submit a plan for equity compliance, with potential reverse stock splits under consideration. Senti Biosciences operates in the biotechnology industry, developing cell therapies.

Senti Biosciences Holdings, Inc. reported that its wholly owned subsidiary issued and sold $4.0 million in aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SPV 24 on August 14, 2026, pursuant to a Securities Purchase Agreement dated April 27, 2026. The filing also disclosed that the company filed a preliminary proxy statement on July 21, 2026, regarding potential transactions involving a merger with an entity affiliated with Celadon and the issuance of contingent value rights potentially paying up to $60.0 million in cash based on regulatory and sales milestones for its product candidate SENTI-202. The company operates in the biotechnology industry, focusing on developing synthetic biology-based therapeutics.

Senti Biosciences Holdings, Inc. entered into a merger agreement on July 14, 2026, with an affiliate of its largest stockholder, Celadon Partners, to sell substantially all of its business and pipeline. The company will remain public but streamlined, focusing on its Regulator Dial technology platform for Rett syndrome and tumor-infiltrating lymphocyte therapies. Stockholders will receive contingent value rights (CVRs) that may provide cash payments totaling up to $60 million based on regulatory and commercial milestones for SENTI-202. The transaction is subject to stockholder approval and is expected to close in the third quarter of 2026. Senti Biosciences is a synthetic biology company developing controllable therapies for gene and cell therapy.